Fucoxanthin enhances cisplatin-induced cytotoxicity via NFκB-mediated pathway and downregulates DNA repair gene expression in human hepatoma HepG2 cells

Marine Drugs

Volumn 11, Issue 1, 2013, Pages 50-66

  Liu, Cheng Ling ^a   Lim, Yun Ping ^b,c   Hu, Miao Lin ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cisplatin; DNA repair; Fucoxanthin; MAPK; NF B; PI3K AKT

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FUCOXANTHIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LY 249002; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SYNAPTOPHYSIN; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ISOLATION; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; MONOTHERAPY; PROTEIN EXPRESSION; REGULATORY MECHANISM; TREATMENT RESPONSE;

EID: 84873174521     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md11010050     Document Type: Article

References (66)

1. Di Bisceglie, A.M. Epidemiology and clinical presentation of hepatocellular carcinoma. J. Vasc. Interv. Radiol. 2002, 13, S169-S171.
2. Montalto, G.; Cervello, M.; Giannitrapani, L.; Dantona, F.; Terranova, A.; Castagnetta, L.A. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann. N. Y. Acad. Sci. 2002, 963, 13-20.
3. Chau, G.Y.; Lui, W.Y.; Tsay, S.H.; Chao, Y.; King, K.L.; Wu, C.W. Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: A case-control study. Ann. Surg. Oncol. 2006, 13, 1329-1337.
4. Tong, S.W.; Yang, Y.X.; Hu, H.D.; An, X.; Ye, F.; Hu, P.; Ren, H.; Li, S.L.; Zhang, D.Z. Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line. J. Cell. Biochem. 2012, 113, 1671-1680.
5. Dietel, M. Molecular mechanisms and possibilities of overcoming drug resistance in gastrointestinal tumors. Recent Results Cancer Res. 1996, 142, 89-101.
6. Go, R.S.; Adjei, A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 1999, 17, 409-422.
7. Cepeda, V.; Fuertes, M.A.; Castilla, J.; Alonso, C.; Quevedo, C.; Perez, J.M. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med. Chem. 2007, 7, 3-18.
8. Zorbas, H.; Keppler, B.K. Cisplatin damage: Are DNA repair proteins saviors or traitors to the cell? ChemBioChem 2005, 6, 1157-1166.
9. Van de Vaart, P.J.; van der Vange, N.; Zoetmulder, F.A.; van Goethem, A.R.; van Tellingen, O.; ten Bokkel Huinink, W.W.; Beijnen, J.H.; Bartelink, H.; Begg, A.C. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur. J. Cancer 1998, 34, 148-154.
10. Kartalou, M.; Essigmann, J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 2001, 478, 23-43.
11. Shahzad, M.M.; Lopez-Berestein, G.; Sood, A.K. Novel strategies for reversing platinum resistance. Drug Resist. Updat. 2009, 12, 148-152.
12. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8, 193-204.
13. Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33, 9-23.
14. Shirota, Y.; Stoehlmacher, J.; Brabender, J.; Xiong, Y.P.; Uetake, H.; Danenberg, K.D.; Groshen, S.; Tsao-Wei, D.D.; Danenberg, P.V.; Lenz, H.J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 2001, 19, 4298-4304.
15. Lord, R.V.; Brabender, J.; Gandara, D.; Alberola, V.; Camps, C.; Domine, M.; Cardenal, F.; Sanchez, J.M.; Gumerlock, P.H.; Taron, M.; et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002, 8, 2286-2291.
16. Zhou, W.; Gurubhagavatula, S.; Liu, G.; Park, S.; Neuberg, D.S.; Wain, J.C.; Lynch, T.J.; Su, L.; Christiani, D.C. Excision repair cross- complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 2004, 10, 4939-4943.
17. Selvakumaran, M.; Pisarcik, D.A.; Bao, R.; Yeung, A.T.; Hamilton, T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003, 63, 1311-1316.
18. Gossage, L.; Madhusudan, S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat. Rev. 2007, 33, 565-577.
19. Bijnsdorp, I.V.; Azijli, K.; Jansen, E.E.; Wamelink, M.M.; Jakobs, C.; Struys, E.A.; Fukushima, M.; Kruyt, F.A.; Peters, G.J. Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells. Biochem. Pharmacol. 2010, 80, 786-792.
20. Nakayama, Y.; Inoue, Y.; Nagashima, N.; Katsuki, T.; Matsumoto, K.; Kadowaki, K.; Shibao, K.; Tsurudome, Y.; Hirata, K.; Sako, T.; et al. Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. Anticancer Res. 2005, 25, 3755-3761.
21. Mori, S.; Takao, S.; Ikeda, R.; Noma, H.; Mataki, Y.; Wang, X.; Akiyama, S.; Aikou, T. Thymidine phosphorylase suppresses Fas-induced apoptotic signal transduction independent of its enzymatic activity. Biochem. Biophys. Res. Commun. 2002, 295, 300-305.
22. Ikeda, R.; Furukawa, T.; Mitsuo, R.; Noguchi, T.; Kitazono, M.; Okumura, H.; Sumizawa, T.; Haraguchi, M.; Che, X.F.; Uchimiya, H.; et al. Thymidine phosphorylase inhibits apoptosis induced by cisplatin. Biochem. Biophys. Res. Commun. 2003, 301, 358-363.
23. Jeung, H.C.; Che, X.F.; Haraguchi, M.; Furukawa, T.; Zheng, C.L.; Sumizawa, T.; Rha, S.Y.; Roh, J.K.; Akiyama, S. Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. Biochem. Pharmacol. 2005, 70, 13-21.
24. Baldwin, A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-?B. J. Clin. Investig. 2001, 107, 241-246.
25. Tabruyn, S.P.; Griffioen, A.W. A new role for NF-?B in angiogenesis inhibition. Cell. Death Differ. 2007, 14, 1393-1397.
26. Andela, V.B.; Gordon, A.H.; Zotalis, G.; Rosier, R.N.; Goater, J.J.; Lewis, G.D.; Schwarz, E.M.; Puzas, J.E.; O'Keefe, R.J. NF?B: A pivotal transcription factor in prostate cancer metastasis to bone. Clin. Orthop. Relat. Res. 2003, 415 (Suppl.), S75-S85.
27. Tomita, M.; Kawakami, H.; Uchihara, J.N.; Okudaira, T.; Masuda, M.; Takasu, N.; Matsuda, T.; Ohta, T.; Tanaka, Y.; Ohshiro, K.; et al. Curcumin (diferuloylmethane) inhibits constitutive active NF-?B, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int. J. Cancer 2006, 118, 765-772.
28. Sharma, H.W.; Narayanan, R. The NF-?B transcription factor in oncogenesis. Anticancer Res. 1996, 16, 589-596.
29. Nakanishi, C.; Toi, M. Nuclear factor-?B inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5, 297-309.
30. Shou, Y.; Li, N.; Li, L.; Borowitz, J.L.; Isom, G.E. NF-?B-mediated up-regulation of Bcl-XS and Bax contributes to cytochrome c release in cyanide-induced apoptosis. J. Neurochem. 2002, 81, 842-852.
31. Sarkar, F.H.; Li, Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 2006, 66, 3347-3350.
32. Yeh, P.Y.; Chuang, S.E.; Yeh, K.H.; Song, Y.C.; Cheng, A.L. Involvement of nuclear transcription factor-?B in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells. Biochem. Pharmacol. 2003, 66, 25-33.
33. Dembitsky, V.M.; Maoka, T. Allenic and cumulenic lipids. Prog. Lipid Res. 2007, 46, 328-375.
34. Sachindra, N.M.; Sato, E.; Maeda, H.; Hosokawa, M.; Niwano, Y.; Kohno, M.; Miyashita, K. Radical scavenging and singlet oxygen quenching activity of marine carotenoid fucoxanthin and its metabolites. J. Agric. Food Chem. 2007, 55, 8516-8522.
35. Heo, S.J.; Jeon, Y.J. Protective effect of fucoxanthin isolated from Sargassum siliquastrum on UV-B induced cell damage. J. Photochem. Photobiol. B 2009, 95, 101-107.
36. Liu, C.L.; Liang, A.L.; Hu, M.L. Protective effects of fucoxanthin against ferric nitrilotriacetate-induced oxidative stress in murine hepatic BNL CL.2 cells. Toxicol. In Vitro 2011, 25, 1314-1319.
37. Liu, C.L.; Chiu, Y.T.; Hu, M.L. Fucoxanthin enhances HO-1 and NQO1 expression in murine hepatic BNL CL.2 cells through activation of the Nrf2/ARE system partially by its pro-oxidant activity. J. Agric. Food Chem. 2011, 59, 11344-11351.
38. Maeda, H.; Hosokawa, M.; Sashima, T.; Takahashi, N.; Kawada, T.; Miyashita, K. Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int. J. Mol. Med. 2006, 18, 147-152.
39. Jeon, S.M.; Kim, H.J.; Woo, M.N.; Lee, M.K.; Shin, Y.C.; Park, Y.B.; Choi, M.S. Fucoxanthin-rich seaweed extract suppresses body weight gain and improves lipid metabolism in high-fat-fed C57BL/6J mice. Biotechnol. J. 2010, 5, 961-969.
40. Maeda, H.; Hosokawa, M.; Sashima, T.; Miyashita, K. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J. Agric. Food Chem. 2007, 55, 7701-7706.
41. Nishino, H.; Tokuda, H.; Murakoshi, M.; Satomi, Y.; Masuda, M.; Onozuka, M.; Yamaguchi, S.; Takayasu, J.; Tsuruta, J.; Okuda, M.; et al. Cancer prevention by natural carotenoids. Biofactors 2000, 13, 89-94.
42. Kim, K.N.; Heo, S.J.; Yoon, W.J.; Kang, S.M.; Ahn, G.; Yi, T.H.; Jeon, Y.J. Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-?B and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur. J. Pharmacol. 2010, 649, 369-375.
43. Zaragoza, M.C.; Lopez, D.; S iz, M.P.; Poquet, M.; Perez, J.; Puig-Parellada, P.; Marmol, F.; Simonetti, P.; Gardana, C.; Lerat, Y.; et al. Toxicity and antioxidant activity in vitro and in vivo of two Fucus vesiculosus extracts. J. Agric. Food Chem. 2008, 56, 7773-7780.
44. Yu, R.X.; Hu, X.M.; Xu, S.Q.; Jiang, Z.J.; Yang, W. Effects of fucoxanthin on proliferation and apoptosis in human gastric adenocarcinoma MGC-803 cells via JAK/STAT signal pathway. Eur. J. Pharmacol. 2011, 657, 10-19.
45. Satomi, Y.; Nishino, H. Implication of mitogen-activated protein kinase in the induction of G1 cell cycle arrest and gadd45 expression by the carotenoid fucoxanthin in human cancer cells. Biochim. Biophys. Acta 2009, 1790, 260-266.
46. Das, S.K.; Hashimoto, T.; Kanazawa, K. Growth inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is associated with down-regulation of cyclin D. Biochim. Biophys. Acta 2008, 1780, 743-749.
47. Yoshiko, S.; Hoyoku, N. Fucoxanthin, a natural carotenoid, induces G1 arrest and GADD45 gene expression in human cancer cells. In Vivo 2007, 21, 305-309.
48. Liu, C.L.; Lim, Y.P.; Hu, M.L. Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar. Drugs 2012, 10, 242-257.
49. Viatour, P.; Bentires-Alj, M.; Chariot, A.; Deregowski, V.; de Leval, L.; Merville, M.P.; Bours, V. NF-?B2/p100 induces Bcl-2 expression. Leukemia 2003, 17, 1349-1356.
50. Minn, A.J.; Rudin, C.M.; Boise, L.H.; Thompson, C.B. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995, 86, 1903-1910.
51. Altaha, R.; Liang, X.; Yu, J.J.; Reed, E. Excision repair cross complementing-group 1: Gene expression and platinum resistance. Int. J. Mol. Med. 2004, 14, 959-970.
52. Ko, J.C.; Su, Y.J.; Lin, S.T.; Jhan, J.Y.; Ciou, S.C.; Cheng, C.M.; Chiu, Y.F.; Kuo, Y.H.; Tsai, M.S.; Lin Y.W. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer 2010, 69, 155-164.
53. Tsai, M.S.; Weng, S.H.; Kuo, Y.H.; Chiu, Y.F.; Lin, Y.W. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1). Mol. Pharmacol. 2011, 80, 136-146.
54. Zhang, W.; Liu, H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002, 12, 9-18.
55. Basu, A.; Tu, H. Activation of ERK during DNA damage-induced apoptosis involves protein kinase C?. Biochem. Biophys. Res. Commun. 2005, 334, 1068-1073.
56. Datta, S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91, 231-241.
57. Mabuchi, S.; Ohmichi, M.; Nishio, Y.; Hayasaka, T.; Kimura, A.; Ohta, T.; Saito, M.; Kawagoe, J.; Takahashi, K.; Yada-Hashimoto, N.; et al. Inhibition of NF?B increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J. Biol. Chem. 2004, 279, 23477-23485.
58. Ohta, T.; Ohmichi, M.; Hayasaka, T.; Mabuchi, S.; Saitoh, M.; Kawagoe, J.; Takahashi, K.; Igarashi, H.; Du, B.; Doshida, M.; et al. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 2006, 147, 1761-1769.
59. Andrieux, L.O.; Fautrel, A.; Bessard, A.; Guillouzo, A.; Baffet, G.; Langouet, S. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res. 2007, 67, 2114-2123.
60. Bessard, A.; Coutant, A.; Rescan, C.; Ezan, F.; Fremin, C.; Courselaud, B.; Ilyin, G.; Baffet, G. An MLCK-dependent window in late G1 controls S phase entry of proliferating rodent hepatocytes via ERK-p70S6K pathway. Hepatology 2006, 44, 152-163.
61. Chen, C.C.; Chen, L.C.; Liang, Y.; Tsang, N.M.; Chang, Y.S. Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-?B and p38 MAPK pathways. Cell. Signal. 2010, 22, 1132-1142.
62. Liu, C.L.; Huang, Y.S.; Hosokawa, M.; Miyashita, K.; Hu, M.L. Inhibition of proliferation of a hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional intercellular communication. Chem. Biol. Interact. 2009, 182, 165-172.
63. Lin, C.Y.; Huang, C.S.; Hu, M.L. The use of fetal bovine serum as delivery vehicle to improve the uptake and stability of lycopene in cell culture studies. Br. J. Nutr. 2007, 98, 226-232.
64. Lim, Y.P.; Kuo, S.C.; Lai, M.L.; Huang, J.D. Inhibition of CYP3A4 expression by ketoconazole is mediated by the disruption of pregnane X receptor, steroid receptor coactivator-1, and hepatocyte nuclear factor 4alpha interaction. Pharmacogenetics Genomics 2009, 19, 11-24.
65. Chen, Y.C.; Kuo, T.C.; Lin-Shiau, S.Y.; Lin, J.K. Induction of HSP70 gene expression by modulation of Ca(+2) ion and cellular p53 protein by curcumin in colorectal carcinoma cells. Mol. Carcinog. 1996, 17, 224-234.
66. Shukla, S.; Maclennan, G.T.; Marengo, S.R.; Resnick, M.I.; Gupta, S. Constitutive activation of P I3 K-Akt and NF-?B during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005, 64, 224-239.